Currently, several molecules aiming to normalize the aberrant function of the mutant ACVR1 are in ongoing clinical trials for the treatment of FOP (https://www.ifopa.org/ongoing_clinical_trials_in_fop, accessed on 11 January 2021). The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.